GEAP202416588A - Pharmaceutical composition comprising budesonide for treating iga nephropathy - Google Patents

Pharmaceutical composition comprising budesonide for treating iga nephropathy

Info

Publication number
GEAP202416588A
GEAP202416588A GEAP202416588A GEAP2024016588A GEAP202416588A GE AP202416588 A GEAP202416588 A GE AP202416588A GE AP202416588 A GEAP202416588 A GE AP202416588A GE AP2024016588 A GEAP2024016588 A GE AP2024016588A GE AP202416588 A GEAP202416588 A GE AP202416588A
Authority
GE
Georgia
Prior art keywords
budesonide
iga nephropathy
composition
opening area
released
Prior art date
Application number
GEAP202416588A
Other languages
English (en)
Georgian (ka)
Inventor
Kari Sandvold
Christian Olle Andreas Pedersen
Eva Kristina Riesel
Lena Margareta Pereswetoff-Morath
Original Assignee
Calliditas Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=85076189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEAP202416588(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB2217146.6A external-priority patent/GB202217146D0/en
Priority claimed from GBGB2217150.8A external-priority patent/GB202217150D0/en
Application filed by Calliditas Therapeutics Ab filed Critical Calliditas Therapeutics Ab
Publication of GEAP202416588A publication Critical patent/GEAP202416588A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GEAP202416588A 2022-01-24 2023-01-24 Pharmaceutical composition comprising budesonide for treating iga nephropathy GEAP202416588A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263302226P 2022-01-24 2022-01-24
US202263302216P 2022-01-24 2022-01-24
GBGB2217146.6A GB202217146D0 (en) 2022-11-16 2022-11-16 New pharmaceutical compositions
GBGB2217150.8A GB202217150D0 (en) 2022-11-16 2022-11-16 New pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GEAP202416588A true GEAP202416588A (en) 2024-11-25

Family

ID=85076189

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202416588A GEAP202416588A (en) 2022-01-24 2023-01-24 Pharmaceutical composition comprising budesonide for treating iga nephropathy

Country Status (14)

Country Link
US (10) US11896719B2 (enExample)
EP (1) EP4469060A1 (enExample)
JP (1) JP2025508321A (enExample)
KR (2) KR20250008979A (enExample)
CN (6) CN120754111A (enExample)
AU (1) AU2023210461A1 (enExample)
CA (1) CA3249575A1 (enExample)
CL (1) CL2024002201A1 (enExample)
CO (1) CO2024009565A2 (enExample)
GE (1) GEAP202416588A (enExample)
IL (1) IL314067A (enExample)
MX (1) MX2024009024A (enExample)
TW (2) TW202547520A (enExample)
WO (1) WO2023139285A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123403A (en) 1977-06-27 1978-10-31 The Dow Chemical Company Continuous process for preparing aqueous polymer microsuspensions
US4502888A (en) 1982-12-13 1985-03-05 The Dow Chemical Company Aqueous dispersions of plasticized polymer particles
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
DE69425453T2 (de) 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
US6239120B1 (en) 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
SE514128C2 (sv) * 1998-03-17 2001-01-08 Pharmalink Ab Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit
CA2377301C (en) 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
DE10004939C1 (de) 2000-02-05 2001-08-23 Lothar Moerl Steuerbare Gasanströmeinrichtung für Strahlschichtapparate
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
ITRM20010614A1 (it) 2001-10-16 2003-04-16 Italchimici S P A Preparazione farmaceutica di una soluzione idro/propilenica di budesonide e suo procedimento di preparazione.
DE10162781A1 (de) 2001-12-20 2003-07-03 Glatt Ingtech Gmbh Strahlschichtapparat zur chargenweisen oder kontinuierlichen Prozessführung und Verfahren zum Betreiben eines Strahlschichtapparates
DE10214002A1 (de) 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
DE10250543A1 (de) 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
WO2004052607A1 (en) 2002-12-10 2004-06-24 Cps Orocel Llc Method of preparing biologically active formulations
DE10322062A1 (de) 2003-05-15 2004-12-02 Glatt Ingenieurtechnik Gmbh Verfahren und Vorrichtung zum Aufbringen von Flüssigkeiten in eine Feststoffströmung eines Strahlschichtapparates
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
AR041873A1 (es) 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
DE102005037630A1 (de) 2005-08-09 2007-02-15 Glatt Gmbh Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung
DE102005060393A1 (de) 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
CN101108171A (zh) 2006-07-17 2008-01-23 复旦大学 一种布地奈德肠溶缓释微丸及其制备方法
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
JP2011506607A (ja) 2007-12-17 2011-03-03 ザリカス インコーポレイティッド 免疫炎症性障害の処置のための治療法
GB0808537D0 (en) * 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
NZ599933A (en) 2009-11-03 2014-08-29 Lipidor Ab Lipid layer forming composition for administration onto a surface of a living organism
JP2014510064A (ja) 2011-02-25 2014-04-24 ザ ジョンズ ホプキンス ユニバーシティ Ｎｒｆ２活性剤としてのカルコン誘導体
AU2012251135A1 (en) 2011-05-02 2013-11-07 Lipidor Ab Treatment of psoriasis
US10034943B2 (en) 2011-05-02 2018-07-31 Lipidor Ab Sprayable topical carrier and composition comprising phosphatidylcholine
EP2591782A1 (en) 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof
WO2013078261A1 (en) 2011-11-22 2013-05-30 The University Of Maryland, Baltimore Treatment of muscular conditions and muscular dystrophies
EP2857399A1 (en) 2013-10-03 2015-04-08 GenKyoTex SA Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction
IN2013MU03373A (enExample) 2013-10-25 2015-07-17 Cadila Healthcare Ltd
WO2015071812A1 (en) 2013-11-18 2015-05-21 Wockhardt Limited Solid oral modified-release composition comprising budesonide or salt thereof
GB201419257D0 (en) 2014-10-29 2014-12-10 Jagotec Ag Pharmaceutical compositions
EP3034500A1 (en) 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
US20190125678A1 (en) 2015-01-30 2019-05-02 Mylan, Inc. Sustained-Release Oral Dosage Forms for Low Aqueous Solubility Compounds
EP3098220A1 (en) 2015-05-28 2016-11-30 GenKyoTex SA Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof
US9707182B2 (en) 2015-09-11 2017-07-18 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical dosage forms of budesonide
AR106330A1 (es) 2015-10-13 2018-01-03 Flexion Therapeutics Inc Formulaciones de corticoesteroide para mantener las concentraciones de corticoesteroide en líquido sinovial
CN105663091A (zh) 2016-01-28 2016-06-15 上海信谊百路达药业有限公司 一种布地奈德肠溶缓释胶囊及其制备方法
US11590084B2 (en) 2016-05-02 2023-02-28 Roman Bielski Microcapsules for controlled delivery of an active pharmaceutical ingredient
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
CA3091443A1 (en) 2018-02-22 2019-08-29 Avior, Inc. Transmucosal film composition and methods of making and using the same
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
EP3628669A1 (en) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
CN110507627B (zh) 2019-09-29 2021-11-02 重庆医药高等专科学校 一种布地奈德的口服控释药物组合物
WO2021127003A1 (en) 2019-12-16 2021-06-24 Children's Medical Center Corporation Treating heart disease in muscular dystrophy patients
CN112999229B (zh) 2019-12-19 2023-01-24 江苏恒瑞医药股份有限公司 一种包含布地奈德的口服药物组合物
US20240197639A1 (en) 2021-04-20 2024-06-20 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Capsule for specific drug delivery and preparation method therefor
TW202302116A (zh) 2021-04-20 2023-01-16 大陸商江蘇恒瑞醫藥股份有限公司 口服腸溶皮質類固醇的藥物組合物
CN115737597A (zh) 2021-09-02 2023-03-07 江苏豪森药业集团有限公司 一种口服的肠溶速释药物组合物、制备方法及其应用
US11896719B2 (en) * 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
US20240033225A1 (en) * 2022-01-24 2024-02-01 Calliditas Therapeutics Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
CA3249575A1 (en) 2023-07-27
US12311057B2 (en) 2025-05-27
US20250381146A1 (en) 2025-12-18
WO2023139285A1 (en) 2023-07-27
IL314067A (en) 2024-09-01
US20250268835A1 (en) 2025-08-28
US11896719B2 (en) 2024-02-13
US20240173264A1 (en) 2024-05-30
TW202339765A (zh) 2023-10-16
TW202547520A (zh) 2025-12-16
AU2023210461A1 (en) 2024-07-18
US20250381147A1 (en) 2025-12-18
US12171883B2 (en) 2024-12-24
EP4469060A1 (en) 2024-12-04
CN120754111A (zh) 2025-10-10
CN120754113A (zh) 2025-10-10
US20240122863A1 (en) 2024-04-18
US20250255824A1 (en) 2025-08-14
US12171882B2 (en) 2024-12-24
JP2025508321A (ja) 2025-03-26
CN120053463A (zh) 2025-05-30
KR102919268B1 (ko) 2026-01-27
KR20240141771A (ko) 2024-09-27
KR20250008979A (ko) 2025-01-16
MX2024009024A (es) 2024-11-08
US20250312283A1 (en) 2025-10-09
TWI896928B (zh) 2025-09-11
US20250057775A1 (en) 2025-02-20
CN121774982A (zh) 2026-04-03
CL2024002201A1 (es) 2025-01-03
CO2024009565A2 (es) 2024-09-19
CN120754112A (zh) 2025-10-10
US20230293444A1 (en) 2023-09-21
US20250312282A1 (en) 2025-10-09
CN121796407A (zh) 2026-04-07

Similar Documents

Publication Publication Date Title
US20220218629A1 (en) Epinephrine fine particles and methods for use thereof
US6340695B1 (en) Rapid onset formulation
US10159656B2 (en) Methods for use of epinephrine fine particles for treatment of conditions responsive to epinephrine
WO2016062283A1 (zh) 抗发炎用药物在制备抑制癌症的医药组合物中的应用
US11607389B2 (en) Delayed release deferiprone tablets and methods of using the same
AU2008262031B2 (en) Extended release formulation of nevirapine
RU2020107732A (ru) Схема дозирования модулятора s1p с немедленным высвобождением
CA2486859A1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
GEAP202416588A (en) Pharmaceutical composition comprising budesonide for treating iga nephropathy
RS58543B1 (sr) Optimizovana farmaceutska formulacija za lečenje zapaljenskih promena ezofagusa
JPH04273822A (ja) 子宮内膜症の治療薬
KR20170021905A (ko) 내장통 치료용 옥시코돈의 사용
KR102696347B1 (ko) 결정성 양진의 치료법
Lucendo et al. Clinical trial: Safety and efficacy of a novel oesophageal delivery system for topical corticosteroids versus placebo in the treatment of eosinophilic oesophagitis
RU2015109933A (ru) Композиции, включающие антитело и камостат мезилат (см)
ES2668943T3 (es) Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz
CA2893480C (en) Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
Mukund et al. Efficacy of various administrative techniques of methylprednisolone on oedema, trismus and pain after lower third molar surgery
Davydova et al. Development of technology and study of combination tablets of prednisolone and loratadine with modified release
AU2020247555B2 (en) Immediate release dosage form
JP2018012693A (ja) ロキソプロフェン又はその塩及びビタミンｅを含有する経口用医薬組成物
Sanap et al. NON SURGICAL MANAGEMENT OF LOW ANAL FISTULA IN ANO WITH SNUHI KSHARASUTRA-A CASE STUDY
WO2024144678A1 (en) Orally disintegrating tablets (odt) formulations for the treatment of flu, common cold and allergic symptoms
IL310420A (en) Treatment of hand eczema with baricitinib
NZ775057B2 (en) Use of reboxetine to treat narcolepsy